Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1161/CIRCINTERVENTIONS.118.007757 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The timing of surgical interventions following the implantation of coronary drug-eluting stents in patients undergoing gastrointestinal cancer surgery: a multicenter retrospective cohort study.
Int J Surg
December 2024
Senior Department of General Surgery, the First Medical Center of Chinese PLA General Hospital, Beijing, China.
Abstract: We aim to investigate the optimal timing for surgical interventions to maximize patient benefit.
Background: The guidelines recommending a minimum deferral of six months for non-cardiac surgeries following drug-eluting stent percutaneous coronary intervention (DES-PCI) do not adequately address the requirements for individuals undergoing gastrointestinal cancer surgery (GCS).
Methods: The study encompassed 2,501 patients treated from January 2017 to December 2021, all of whom underwent GCS within one year after DES-PCI.
Drug-Coated Balloons for the Treatment of Coronary Artery Disease: A Review.
JAMA Cardiol
December 2024
The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Importance: Drug-coated balloon (DCB) angioplasty has emerged as an alternative to drug-eluting stent (DES) implantation for percutaneous coronary intervention (PCI) in patients with coronary in-stent restenosis (ISR) as well as de novo coronary artery disease.
Observations: DCBs are balloons coated with antiproliferative agents and excipients, whose aim is to foster favorable vessel healing after appropriate lesion preparation. By providing homogeneous antiproliferative drug delivery in the absence of permanent foreign body implantation, DCBs offer multiple advantages over DES, including preservation of vessel anatomy and function and positive vessel remodeling.
Anomalous Left Coronary Artery Originating From the Right Coronary Sinus With a Septal Curse in a Patient With Myocardial Infarction Due to Right Coronary Lesion: Innocent Until Proven Otherwise.
Cureus
November 2024
Cardiology Department, Medical School, Agostinho Neto University, Luanda, AGO.
Coronary artery anomalies (CAAs) are rare and challenging, with increased diagnoses due to advanced cardiovascular imaging, even in low-income countries where diagnostic and therapeutic approaches can be difficult. This case report details a 65-year-old Black male patient with a history of hypertension and smoking who presented with a myocardial infarction. Despite no significant abnormalities apart from the infarction, invasive coronary angiography revealed a dominant right coronary artery (RCA) and an anomalous left main coronary artery (LMCA) originating from the right coronary sinus, bifurcating into the left anterior descending artery and circumflex artery.
View Article and Find Full Text PDFOff-pump coronary artery bypass grafting versus percutaneous coronary intervention with second-generation drug-eluting stents for coronary artery revascularization.
J Int Med Res
December 2024
Department of Cardiovascular Surgery, Shanxi Cardiovascular Hospital (Institute), Shanxi Clinical Medical Research Center for Cardiovascular Disease, Taiyuan, China.
Objective: This study compared the clinical efficacy of off-pump coronary artery bypass grafting (OPCAB) with percutaneous coronary intervention (PCI) in the treatment of left main coronary artery and/or triple-vessel disease (LM and/or TVD).
Methods: We retrospectively enrolled 1484 consecutive patients with LM and/or TVD in Shanxi Cardiovascular Hospital from January 2015 to December 2022 and divided them into the OPCAB group (n = 583) and the PCI group (with second-generation drug-eluting stents) (n = 901). Propensity score matching was used for 316 equally matched pairs of patients in the groups.
Indobufen-based Dual Antiplatelet Therapy in Patients with Multivessel Coronary Disease Undergoing Drug-eluting Stent Implantation Insight From the OPTION Trial.
Am Heart J
December 2024
Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai, China; Department of Cardiology, Shanghai Geriatric Medical Center, Shanghai, China. Electronic address:
Background: It remains unclear whether indobufen-based dual antiplatelet therapy (DAPT) preserves ischemic protection while limiting bleeding risk in patients with multivessel coronary disease (MVD). This study aimed to investigate the efficacy and safety of indobufen-based DAPT in patients with MVD.
Methods: Patients in the OPTION trial were stratified based on the presence of MVD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!